Provectus Biopharma approves up to $10M convertible loan financing for drug development

PROVECTUS BIOPHARMACEUTICALS, INC.

Board approved 2025 Term Sheet to arrange up to $10M unsecured convertible loan in tranches.
Loan bears 8% annual interest; principal and interest convertible into Series D-1 Preferred at $2.8620 per share, each convertible into 10 common shares.
Proceeds to fund drug discovery and development program and general & administrative expenses.
Company closed 2024 Financing with $1M in convertible promissory notes received as of January 15, 2025.
Issuance of notes exempt from registration under Section 4(a)(2) or Rule 506 of Regulation D.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.